

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
1	19/YH/0013	255993	Phase 3 - XL184 in Combination with Atezolizumab vs Sorafenib in HCC	11/12/2018	12/08/2019	15/02/2019	18/07/2019	12/08/2019	20/08/2019	16/12/2019	Neither
2	18/NW/0699	241427	TACE-3	14/01/2019	05/09/2019	21/03/2019	23/10/2019	25/10/2019			Sponsor
3	18/SS/0085	243640	Alpha-2 agonists for sedation (A2B Trial)	31/05/2019	02/08/2019	14/12/2018	09/08/2019	20/08/2019	12/12/2019	07/01/2020	Sponsor
4	19/YH/0079	259791	Cabozantinib in Radioiodine-Refractory Differentiated Thyroid Cancer	11/03/2019	19/08/2019	09/05/2019	31/07/2019	19/08/2019	30/08/2019		Neither
5	17/SC/0476	186573	MERIT	25/07/2018	11/07/2019	07/11/2017	25/07/2019	30/07/2019	18/10/2019	04/12/2019	Both
6	19/EE/0105	259619	JUVE-X/ Long term safety and efficacy of baricitinib	10/04/2019	12/07/2019	24/06/2019	28/08/2019	29/08/2019	02/12/2019	31/01/2020	Neither
7	18/SC/0342	247085	Phase III Trial of AMT-061 in adults with haemophilia B	14/05/2019	15/07/2019	06/09/2018	09/07/2019	18/07/2019	30/07/2019		Sponsor
8	19/SW/0039	253195	GLOW	30/08/2018	16/07/2019	20/05/2019	30/10/2019	01/11/2019	15/11/2019	30/12/2019	NHS Provider
9	19/EE/0185	260536	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC)	03/06/2019	19/07/2019	26/07/2019	05/09/2019	09/09/2019	07/10/2019	14/10/2019	Sponsor
10	19/LO/0714	246398	Red cell transfusion in Paediatric Allogeneic HSCT (RePAST)	07/05/2019	24/07/2019	24/06/2019	30/08/2019	03/09/2019	03/09/2019	18/09/2019	Benchmark Met
11	19/YH/0067	254066	CANOPY-1	23/03/2019	26/07/2019	23/04/2019	07/08/2019	14/08/2019	19/08/2019		Sponsor
12	19/LO/0952	262142	KEYNOTE-921 - Phase 3 Study of Pembrolizumab plus Docetaxel in mCRPC	08/02/2019	26/07/2019	14/08/2019	05/08/2019	06/08/2019	28/08/2019		Neither
13	19/SC/0253	264426	Open label study of BI 754132 in patients with Geographic Atrophy.	23/05/2019	31/07/2019	08/07/2019	02/08/2019	02/08/2019	20/08/2019	02/10/2019	Benchmark Met
14	18/NE/0282	248188	20170534: Extension of Study 20130173 in Children and Young Adults with OI	22/08/2018	05/08/2019	13/03/2019	16/08/2019	16/08/2019	20/08/2019	09/10/2019	Benchmark Met
15	19/SC/0086	249778	A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors	19/10/2018	05/08/2019	06/06/2019	02/10/2019	07/11/2019	07/11/2019		Sponsor
16	19/NI/0110	260538	EluNIR HBR study	25/03/2019	05/08/2019	19/07/2019	04/08/2019	19/08/2019	25/08/2019	20/09/2019	Benchmark Met
17	19/EM/0020	252705	TAPER	03/07/2019	21/08/2019	23/05/2019	22/08/2019	27/08/2019	11/10/2019		Sponsor
18	19/NW/0442	262204	JUVE BRIGHT	18/06/2019	28/08/2019	06/08/2019	29/08/2019	02/09/2019	18/09/2019	31/10/2019	Benchmark Met
19	19/YH/0158	262107	TRANSITION	13/06/2019	28/08/2019	26/07/2019	04/09/2019	12/09/2019	03/10/2019	12/11/2019	Sponsor
20	19/LO/1057	261202	Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC (KEYNOTE-641)	08/02/2019	30/08/2019	28/08/2019	02/09/2019	12/09/2019	12/09/2019	29/10/2019	Benchmark Met
21	18/NW/0694	248847	Derby - Geographic Atrophy secondary to AMD	06/08/2018	30/08/2019	07/12/2018	02/09/2019	02/09/2019	13/11/2019	13/01/2020	Sponsor
22	19/YH/0247	266732	4451-STEP TEENS-semaglutide effect in adolescents with obesity	24/07/2019	27/09/2019	25/09/2019	30/10/2019	06/11/2019	12/11/2019	15/01/2020	Neither
23	16/SC/0651	213404	High Energy High Protein Peptide Feed Study	01/08/2019	06/09/2019	13/01/2017	12/09/2019	13/09/2019	03/10/2019	12/11/2019	Benchmark Met
24	17/LO/1476	224732	A phase 2a Study in Adult Volunteers with Sickle Cell Anaemia - 001	20/06/2019	09/09/2019	19/10/2017	04/09/2019	10/09/2019	12/09/2019	16/10/2019	Benchmark Met

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
25	19/NW/0443	264683	JAHU; Oral baricitinib in patients 1-18 years with systemic JIA	25/06/2019	11/09/2019	19/08/2019	14/10/2019	14/10/2019	06/11/2019		Neither
26	19/LO/0928	262406	Pembrolizumab+Olaparib vs Abiraterone Acetate or Enzalutamide in mCRPC	31/05/2019	12/09/2019	10/09/2019	10/10/2019	16/10/2019	17/10/2019	20/02/2020	Neither
27	17/LO/0980	219505	HALT - Stereotactic Body Radiotherapy for the treatment of OPD	02/09/2019	19/09/2019	10/07/2017	02/12/2019	02/12/2019	03/12/2019		NHS Provider
28	19/NW/0482	269475	Kepler	18/06/2019	20/09/2019	27/09/2019	09/10/2019	14/10/2019	17/10/2019	05/11/2019	Benchmark Met
29	19/EM/0151	259687	Cerebral Palsy-0075/0140-Teva	19/02/2019	23/09/2019	16/07/2019	14/10/2019	18/10/2019	25/10/2019		Neither
30	19/YH/0099	257815	LAT8881 in Neuropathic Pain	30/11/2018	26/09/2019	05/09/2019	26/09/2019	01/10/2019	19/11/2019	12/12/2019	Sponsor
31	18/SC/0427	220853	The Bronchiolitis Endotracheal Surfactant Study (BESS)	21/06/2019	30/09/2019	15/10/2018	30/09/2019	01/10/2019	10/10/2019	20/11/2019	Benchmark Met
32	19/SC/0415	269249	MELODY	20/08/2019	04/10/2019	04/10/2019	17/10/2019	18/10/2019	06/11/2019		Neither
33	19/SC/0416	269256	Medley D5290C00005	20/08/2019	04/10/2019	04/10/2019	17/10/2019	18/10/2019	29/10/2019		Neither
34	19/LO/1367	266879	Cancer-0456/0232-Regeneron	04/06/2019	04/10/2019	04/10/2019	16/12/2019	19/12/2019	24/12/2019	03/01/2020	Both
35	19/YH/0301	268446	A Phase 2 study of ABBV-3067 alone and in combination with ABBV-2222	05/07/2019	27/11/2019	31/10/2019					Sponsor
36	19/SC/0112	259372	ADJUST	09/05/2019	16/12/2019	12/11/2019	18/12/2019	18/12/2019	19/06/2020		Sponsor
37	19/LO/1551	269540	NETTER-2	26/09/2019	20/12/2019	06/12/2019	26/12/2019	28/01/2020	04/02/2020		Sponsor
38	19/SW/0166	268532	REVIVAL Trial	17/01/2019	02/01/2020	01/11/2019	02/01/2020	04/02/2020	06/02/2020	28/02/2020	Benchmark Met
39	19/LO/1153	262506	Fostamatinib disodium in the treatment of wAIHA	17/06/2019	07/01/2020	16/09/2019					Neither
40	19/NW/0135	252254	COSI	13/05/2019	08/01/2020	17/05/2019	04/03/2020	04/03/2020	22/06/2020		Sponsor
41	19/WA/0209	266031	ASICS v1.0	02/08/2019	09/01/2020	04/09/2019	13/02/2020	13/02/2020	09/03/2020		Sponsor
42	19/LO/1336	256748	SIOP-HRMB	18/11/2019	15/01/2020	13/11/2019					Sponsor
43	19/NW/0018	232386	Evaluation of Ketoflo	17/10/2018	24/01/2020	15/03/2019	20/02/2020	24/02/2020	24/02/2020		Neither
44	19/ES/0126	271121	RAGNAR - 42756493CAN2002	19/08/2019	28/01/2020	01/11/2019	28/01/2020	28/01/2020	29/01/2020	31/01/2020	Benchmark Met
45	19/EE/0322	265824	The PARROT-2 Trial	20/01/2020	31/01/2020	11/11/2019	07/02/2020				Neither
46	19/LO/1866	270431	PLUTO	17/09/2019	05/02/2020	22/12/2019	24/02/2020	24/02/2020			Neither
47	19/NW/0032	239520	ELEMENT	01/08/2019	07/02/2020	20/02/2019	07/02/2020	10/02/2020	14/02/2020		Neither
48	20/WA/0054	264043	Status Assessment of Participants enrolled in TOWER study	10/01/2020	17/02/2020	06/02/2020	21/02/2020	24/02/2020	05/03/2020	17/03/2020	Benchmark Met
49	18/SW/0254	248635	Short term Water-only Fasting prior to chemotherapy Trial (SWiFT)	13/12/2019	19/02/2020	25/01/2019	04/03/2020	04/03/2020	09/03/2020		Neither
50	19/NW/0716	273613	A Study Evaluating the Safety of Elexacaftor Combination Therapy	17/10/2019	04/03/2020	17/01/2020	18/03/2020	19/03/2020	24/03/2020	11/05/2020	Benchmark Met
51	18/SC/0610	242511	POPPY	18/12/2019	05/03/2020	08/01/2019	05/03/2020				Neither
52	16/EE/0514	207302	ATOMIC-Meso Phase 2/3 Study	05/02/2020	16/03/2020	28/02/2017					Neither
53	20/EE/0101	281712	RECOVERY trial	17/03/2020	23/03/2020	17/03/2020	23/03/2020	26/03/2020	01/04/2020	07/04/2020	Benchmark Met
54	19/EM/0086	254831	Open-label Extension Study of IMR-687	05/12/2019	31/03/2020	02/08/2019	07/05/2020	11/05/2020	13/05/2020	27/05/2020	Benchmark Met
55	18/LO/0660	237150	REMAP-CAP	06/04/2020	14/04/2020	23/07/2018	17/04/2020	17/04/2020	21/04/2020	25/04/2020	Benchmark Met

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
56	20/SC/0145	281259	A phase I/II trial of a candidate COVID-19 vaccine (COV001)	15/04/2020	21/04/2020	26/03/2020	20/04/2020	21/04/2020	22/04/2020	22/04/2020	Benchmark Met
57	19/ES/0136	270742	MOMENTUM.	14/02/2020	12/05/2020	31/01/2020					Not yet 70 days
58	19/LO/1313	243252	A dose finding study of OligoG in patients with Cystic Fibrosis	21/02/2019	13/05/2020	06/03/2020					Not yet 70 days
59	20/SC/0179	281904	Investigating a Vaccine Against COVID-19 (COV002)	15/04/2020	20/05/2020	04/05/2020	20/05/2020	20/05/2020	20/05/2020	25/05/2020	Benchmark Met
60	20/EE/0135	282213	TACTIC-R (COVID-19)	13/05/2020	29/05/2020	06/05/2020	02/06/2020	12/06/2020	15/06/2020		Not yet 70 days
61	19/NE/0145	254931	FaR-RMS	24/07/2019	01/06/2020	22/07/2019					Not yet 70 days
62	20/SC/0108	278921	First-in Human trial of BI 764524 in diabetic retinopathy	03/03/2020	09/06/2020	09/06/2020					Not yet 70 days
63	20/WA/0098	275346	VIALE-M	08/01/2020	17/06/2020	08/04/2019					Not yet 70 days
64	19/NE/0215	234453	Myeloma XIV (FiTNEss)	23/08/2019	17/12/2019	07/11/2019					Sponsor
65	19/NW/0025	253778	Supported exercise training for men on ADT (WP 3)	13/06/2019	30/08/2019	18/02/2019	24/09/2019	16/09/2019	01/10/2019	01/10/2019	Benchmark Met
66	19/YH/0276	258327	HEMISPAIRE	30/07/2019	08/11/2019	01/11/2019	22/11/2019	08/01/2020	08/01/2020		Neither
67	19/YH/0316	251056	Knee Incision Trial	06/07/2018	23/12/2019	23/12/2019	23/12/2019	29/01/2020	07/02/2020		Neither